English Spanish Chinese Russian German French Japanese Hindi Telugu Tamil

Jornal de Ciências Biomédicas

  • ISSN: 2254-609X
  • Índice h do diário: 15
  • Pontuação de citação de diário: 5.60
  • Fator de impacto do periódico: 4.85
Indexado em
  • Genamics JournalSeek
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • Diretório de Indexação de Periódicos de Pesquisa (DRJI)
  • OCLC- WorldCat
  • Google Scholar
  • SHERPA ROMEU
  • Laboratórios secretos do mecanismo de pesquisa
Veja mais
Compartilhe esta página

Abstrato

Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, fficacy and Resistance

Dae Won Kim, Marc Uemura and Adi Diab

Since pembrolizumab (Keytruda®) was approved for advanced melanoma in September 2014, multiple PD-1 blockade agents have been explored in other malignancies. Emerging clinical data has demonstrated durable clinical activity and safety of PD-1/L1 blockade agents in diverse cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial cancer, Hodgkin lymphoma, and head and neck cancer. Thus, PD-1/L1 blockade agents have led to a paradigm shift in cancer therapy. In this review, current indications of PD-1 blockade agents in advanced solid malignancies will be discussed.